Tuberculosis Therapy: Smallest Particles Will Deliver the Drug to the Lungs in Future

Therapy of the dangerous infectious disease of tuberculosis faces the challenge of pathogens frequently being resistant to several common antibiotics. Researchers of Karlsruhe Institute of Technology (KIT) have now developed nanoparticles to deliver new antibiotics directly to the lungs in future. Surfactants ensure that the highly fat-soluble antibiotics disperse very finely in water and can be inhaled. First tests at the Research Center Borstel, Leibniz Lung Center, reveal a high effectiveness and good compatibility of the nanocarriers of antibiotics. The researchers report in ACS Nano. (DOI: 10.1021/acsnano.3c01664)

What You Should Know About Mpox

Find out what special pathogens expert Erika Cheung, MSN, RN, CPN, has to say about the disease, which the WHO has declared a public health emergency of international concern. Since May 18, 2022, cases of mpox have been spreading in the United States, including California. On July 23, 2022, the World Health Organization (WHO) declared the current outbreak a public health emergency of international concern.

New Low-cost Device Rapidly, Accurately Detects Hepatitis C Infection

The entire virus detection process is executed inside a uniquely designed, portable, inexpensive, disposable, and self-driven microfluidic chip. The fully automated sample-in–answer-out molecular diagnostic set-up rapidly detects Hepatitis C virus in about 45 minutes and uses relatively inexpensive and reusable equipment costing about $50 for sample processing and disease detection. The disposable microfluidic chip also offers shorter times for a reliable diagnosis and costs about $2.

Genetics/biotech expert offers comments & availability on IVG (in vitro gametogenesis) major breakthrough

A groundbreaking study demonstrating the most advanced form of in vitro gametogenesis (making eggs from stem cells, IVG) was published Thursday in Science. See STAT’s coverage of the study.  Regarding the study and breakthrough, Dr. Kevin Doxzen offers the below comments…

GLOBAL POLIOVIRUS RISK MANAGEMENT AND MODELING

Launched in 1988, the Global Polio Eradication Initiative (GPEI) stands out as one of the largest, internationally coordinated global public health major projects conducted to date, with cumulative spending of over $16.5 billion for 1988–2018, according to the World Health Organization (WHO). More than 30 years later, stubborn outbreaks of wild poliovirus still occur in Afghanistan and Pakistan, where cases have been increasing since 2018. The global eradication of polio continues to be an elusive goal.

Remdesivir for COVID-19: FDA Approved but Still Unproven

In a review of evidence from the most reliable data from randomized trials to find likely small-to-moderate effects of remdesivir, researchers say that totality of evidence compiled before the WHO trial results justifies compassionate use of remdesivir for severely ill patients. A smaller trial in China showed significantly decreased mean recovery time but no suggestion of a mortality benefit. ACTT-1 found the same mean recovery time and a suggestion of a mortality benefit that did not achieve statistical significance.

WashU Expert: America gains nothing by leaving WHO

President Donald Trump’s recent announcement to suspend U.S. funding to, and withdraw from, the World Health Organization is “counter to our interests in addressing our needs to save the lives and further the health of Americans, as well as an abandonment of America’s position as a global leader,” says the director of Washington University in St.

WashU Expert: WHO withdrawal may not be legal

President Donald Trump announced July 7 that the United States has officially begun to withdraw from the World Health Organization (WHO). Trump may or may not have the authority to do so, says an expert on health law at Washington University in St. Louis.“It’s not clear that the president can unilaterally withdraw the United States from membership in the WHO,” said Rachel Sachs, associate professor of law and a renowned expert on health policy and drug law.

ARN Board Member Maureen Musto Selected for Development Group Working on the World Health Organization “Rehabilitation 2030” Initiative

The Association of Rehabilitation Nurses is proud to announce that ARN Board Member Maureen Musto, MS RN APRN-CNS ACNS-BC CRRN, has been selected to serve on the Development Group for Traumatic Brain Injury and Parkinson’s Disease working on development of the World Health Organization (WHO) Rehabilitation Programme’s Package of Interventions for Rehabilitation (PRI).

How can we be more sure social media posts about coronavirus are accurate?

As COVID-19 has increasingly isolated us from each other, we’re relying more and more on social media for a sense of connection and as a source of information about the virus and it’s spread. But how can we be more confident that what we’re seeing is accurate?

New Tool Monitors Real Time Mutations In Flu

A Rutgers-led team has developed a tool to monitor influenza A virus mutations in real time, which could help virologists learn how to stop viruses from replicating. The gold nanoparticle-based probe measures viral RNA in live influenza A cells, according to a study in The Journal of Physical Chemistry C. It is the first time in virology that experts have used imaging tools with gold nanoparticles to monitor mutations in influenza, with unparalleled sensitivity.

Epilepsy is a threat to public health, says international report

Worldwide, more than 50 million people are living with epilepsy. As many as 37 million are not receiving treatment, though it can cost as little as US$5 a year and eliminates seizures about two-thirds of the time. These findings and many others are published in “Epilepsy: A public health imperative”, a report produced by ILAE, the World Health Organization and the International Bureau for Epilepsy.

Epilepsy is a threat to public health, says international report

Worldwide, more than 50 million people are living with epilepsy. As many as 37 million are not receiving treatment, though it can cost as little as US$5 a year and eliminates seizures about two-thirds of the time. These findings and many others are published in “Epilepsy: A public health imperative”, a report produced by ILAE, the World Health Organization and the International Bureau for Epilepsy.